This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MiMedx Is Issued Three New U.S. Patents For Placental Tissue Allografts

Stocks in this article: MDXG

MARIETTA, Ga., June 11, 2013 /PRNewswire/ --  MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of three newly issued patents related to tissue allografts derived from the placenta.

The U.S Patent Office has issued to MiMedx® U.S. Patent Number 8,409,626, "Placental Tissue Grafts" with a grant date of April 2, 2013. The U.S. Patent Office has also issued to MiMedx® U.S. Patent Number 8,460,715, "Placental Tissue Grafts" and U.S. Patent Number 8,460,716, "Method for Applying a Label to a Placental Tissue Graft", both with a grant date of June 11, 2013. The new patents relate to the Company's placental tissue allografts, including AmnioFix® and EpiFix® brand allografts.

Human amnion/chorion tissue is rich in cytokines and growth factors known to promote wound healing; however, preservation of the biological activities of therapeutic allografts during processing is challenging. The dehydrated human amnion/chorion membrane tissue allografts ("dHACM") resulting from the MiMedx proprietary PURION® process have solved this challenge. PURION® processed dHACM retains biologically active growth factors and regulatory factors that are in part responsible for its clinical effectiveness in wound healing and other applications.

"We are pleased to have been granted three new patents during the second quarter of this year. These three newly issued patents now give us a total of eight dHACM-based U.S. patents that have been issued to MiMedx®," said Parker H. "Pete" Petit, Chairman and CEO. "We are also pleased that our allografts from our proprietary AmnioFix® and EpiFix® technologies are continuing to gain excellent reception among the physician community and the private and public sector insurance carriers."

"We are being extremely diligent about the protection of our AmnioFix® and EpiFix® intellectual property. At our direction, our patent counsel is currently reviewing certain issues that have come to our attention related to potential infringement from competing products on our intellectual property. We will use all of the legal remedies and means available to be certain that our intellectual property is respected," added Petit.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs